lifitegrast lifitegrast lifitegrast, sold under the brand name xiidra (/ˈzaɪdrə/), is a medication for the treatment of signs and symptoms of dry eye, a syndrome called keratoconjunctivitis sicca. lifitegrast reduces inflammation by inhibiting inflammatory cell binding. it is often used in conjunction with ciclosporin (ikervis, restasis, or cequa) for dry eye treatment including meibomian gland dysfunction and inflammatory dry eye. lifitegrastclinical datatrade namesxiidraother namessar-1118ahfs/drugs.commonographmedlineplusa616039pregnancycategory au: b1 routes ofadministrationeye dropsatc codes01xa25 (who) legal statuslegal status au: s4 (prescription only) us: ℞-only identifiers iupac name n--3-(methylsulfonyl)-l-phenylalanine cas number1025967-78-5pubchem cid11965427chemspider10139520unii038e5l962wkeggd10374chebichebi:133023 ychemblchembl2048028comptox dashboard (epa)dtxsid60145345 echa infocard100.245.695 chemical and physical dataformulac29h24cl2n2o7smolar mass615.48 g·mol−13d model (jsmol)interactive image smiles cs(=o)(=o)c1cccc(c1)c(c(=o)o)nc(=o)c2c(cc3c(c2cl)ccn(c3)c(=o)c4ccc5ccoc5c4)cl inchi inchi=1s/c29h24cl2n2o7s/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23h,7,9,12,15h2,1h3,(h,32,34)(h,36,37)/t23-/m0/s1key:jfozkmsjyspyln-qhcpkhfhsa-n adverse effects common side effects in clinical trials were eye irritation, discomfort, blurred vision, and dysgeusia (a distortion of the sense of taste). pharmacology lifitegrast is supplied as an eye drop. mechanism of action lifitegrast inhibits an integrin, lymphocyte function-associated antigen 1 (lfa-1), from binding to intercellular adhesion molecule 1 (icam-1). this mechanism down-regulates inflammation mediated by t lymphocytes. history lifitegrast was initially designed and developed by sarcode bioscience which was acquired by shire in 2013, which submitted a new drug application to the us food and drug administration (fda) in march 2015. the fda granted shire a priority review a month later, and requested additional clinical data, which were supplied in january 2016; approval was granted on 11 july 2016. lifitegrast was approved by health canada in january 2018, and available in canadian pharmacies as of march 2018. shire was acquired by takeda pharmaceutical company in late 2018. in may 2019 novartis reached an agreement to purchase the assets associated with lifitegrast. novartis will pay takeda an upfront payment of $3.4 billion, while the latter drugmaker is eligible for milestone payments of as much as $1.9 billion. novartis noted that the drug amassed approximately $400 million in revenue in 2018.